Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic

Hepatology Research

Volumn 43, Issue 4, 2013, Pages 339-346

  Nishida, Tsutomu ^a,b   Hiramatsu, Naoki ^a   Mizuki, Masao ^b   Nagatomo, Izumi ^b   Kida, Hiroshi ^b   Tazumi, Keiko ^b   Shinzaki, Shinichiro ^a,b   Miyazaki, Masanori ^a   Yakushijin, Takayuki ^a   Tatsumi, Tomohide ^a   Iijima, Hideki ^a   Kiso, Shinichi ^a   Kanto, Tatsuya ^a   Tsujii, Masahiko ^a   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biologic therapy; Chemotherapy; Hepatitis B virus reactivation; Outpatient

Indexed keywords

ADEFOVIR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ENTECAVIR; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLYCYRRHIZIC ACID; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; INTERLEUKIN 2; IRINOTECAN; LAMIVUDINE; LEVOLEUCOVORIN; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; PREDNISOLONE; RITUXIMAB; TRASTUZUMAB; VINDESINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BILE DUCT CANCER; BIOLOGICAL THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MACROGLOBULINEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTPATIENT DEPARTMENT; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT SAFETY; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOMA; STOMACH CANCER; VIRUS CARRIER; VIRUS REACTIVATION;

EID: 84871752851     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01073.x     Document Type: Article

References (22)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
3. Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987; 126: 492-9.
4. Purcell RH. The discovery of the hepatitis viruses. Gastroenterology 1993; 104: 955-63.
5. Yokosuka O, Kurosaki M, Imazeki F etal. Management of hepatitis B: consensus of the Japan Society of Hepatology 2009. Hepatol Res 2011; 41: 1-21.
6. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-12.
7. Koo YX, Tay M, Teh YE etal. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90: 1219-23.
8. Tsubouchi H, Kumada H, Kiyosawa K etal. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection - joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis Kanzo 2009; 50: 38-42. (In Japanese.)
9. Mochida S, Takikawa Y, Nakayama N etal. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011; 41: 805-12.
10. Yeo W, Chan PK, Zhong S etal. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
11. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
12. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-71.
13. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992; 16: 13-8.
14. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986; 83: 1627-31.
15. Yeo W, Zee B, Zhong S etal. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.
16. Yeo W, Lam KC, Zee B etal. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-6.
17. Zhong S, Yeo W, Schroder C etal. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 55-9.
18. Hsu CH, Hsu HC, Chen HL etal. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 2004; 24: 3035-40.
19. Kim MK, Ahn JH, Kim SB etal. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 2007; 22: 237-43.
20. Yeo W, Chan PK, Hui P etal. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70: 553-61.
21. Tran TT, Rakoski MO, Martin P, Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 2010; 31: 240-6.
22. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 2010; 17: 32-8.